Brain Mural Cells Express CAR T-cell Target.

Evidence continues to grow that KRAS, once considered an "undruggable" target, can be targeted successfully in non-small cell lung cancer. In a phase I trial, the KRAS inhibitor sotorasib elicited responses in about a third of patients with the disease and was generally well tolerated.